i remember medical school early days residency medications available treat psychosis neuroleptics patients hated taking high potency medicines like haldol prolixin left people rigid pill rolling movements fingers cogwheeling joints walked liked zombies lower potency medications like mellaril left people drooling sedated i heard medications described like molasses poured brain cajole people taking like medications people side effects got better usual i soon realized best thing zyprexa became evident problems i discuss patients mind taking look like zombies obvious psychiatric patients complain feeling badly feel like revolutionary change psychiatry i remember disappointing distressing realize novel anti psychotics associated weight gain people sometimes lot weight gained diabetes lipid abnormalities sometimes i wondered things things one asking problems reversible medications stopped i patient became diabetic rather dramatic fashion i might add glucose topping whose diabetes reversed medication stopped true everyone someone took low dose need basis severe agitation catastrophic distress something i see fair amount either instead benzodiazepine addition one low dose short period time subject problems people schizophrenia later years going along fine living independently seeing family going church looking quite well happy treatment also diabetes cardiac risk factors i tried change medications lower risk long dormant schizophrenia became evident i decided settle risk benefit discussion leave patients dose matter fact lipid metabolism change mean patient greater risk cardiovascular events laboratory values discussing i pleased see i one thinking journal clinical psychiatry december published study cardiovascular outcomes diabetes mellitus among users second generation antipsychotics cirtome et al i thought i summarize finding retrospective study done data extracted database patients started nd generation antipsychotic years old included study index date determined patient needed fill least days worth medicine index date patient followed switch discontinuation medicine disenrollment health plan end study cardiovascular event procedure diagnosis diabetes patients followed medications risperdal zyprexa seroquel geodon latuda saphis sample size clozapine deemed insufficient dose index drug categorized high medium low though range ability given mg medium smaller pill available mg study included patients divided risperdal zyprexa seroquel geodon abilify every cohort common diagnosis major depression followed bipolar disorder patients less cohort diagnosis schizophrenia patients medium level dosing medications diagnosis diabetes required diagnosis made days medication patients excluded idea likely pre existing condition results showed new diagnosis diabetes common cardiovascular event rates diagnosis diabetes per person years number subsets abilify group matched comparator drug i sad report i bit lost pages data abilify vs comparator vs zyprexa vs seroquel vs geodon vs previous studies shown decrease risk diabetes abilfy geodon study find significant difference medications risk diabetes authors speculated perhaps high risk diabetes preferentially prescribed abilify findings past studies preferential prescribing occurred patients abilify would higher risk lower rate would expected could washed speculation i totally sold leave significant difference causing diabetes medications authors note also may confounding issues race smoking status available claims data also death rates could examined insurance claims filed dead people i would interested low dose cutoff abilify raised mg mg comparison zyprexa showed small statistically significant reduction risk olanzapine olanzapine generic zyprexa huh risk diabetes mg abilify considered low addressing psychosis zyprexa higher dose abilify mg compared zyprexa presumably indicated dose less likely cause diabetes overall difference drugs diabetes expected decrease diabetes abilify geodon found risk heart failure stroke rose comparator drugs compared abilify low frequency events may considered small magnitude given low incidence rates likely clinically meaningful individual practice level compared abilify increased risk stroke heart failure cardiovascular event seroquel compared abilify increased risk stroke cardiovascular event zyprexa risperdal compared abilify increased risk geodon measure compared abilify increased risk stroke zyprexa